Toxic epidermal necrolysis in adult T cell leukemia/lymphoma treated with mogamulizumab
暂无分享，去创建一个
M. Taniwaki | J. Kuroda | Y. Tsutsumi | E. Kawata | N. Uoshima | H. Uchiyama | T. Akaogi | Yutaka Kobayashi | J. Yamaguchi | K. Tanba | R. Isa | Kanade Katsura
[1] J. Kato,et al. Late onset toxic epidermal necrolysis induced by mogamulizumab, an anti‐CC chemokine receptor 4 antibody for the treatment of adult T‐cell leukaemia/lymphoma , 2017, Hematological oncology.
[2] R. Schwartz,et al. Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. , 2013, Journal of the American Academy of Dermatology.
[3] S. Iida,et al. Stevens–Johnson Syndrome associated with mogamulizumab treatment of adult T‐cell leukemia / lymphoma , 2013, Cancer science.
[4] M. Iijima,et al. Erythema multiforme, Stevens–Johnson syndrome and toxic epidermal necrolysis: Frozen‐section diagnosis , 2010, The Journal of dermatology.
[5] T. Shiohara,et al. Defective Regulatory T Cells In Patients with Severe Drug Eruptions: Timing of the Dysfunction Is Associated with the Pathological Phenotype and Outcome1 , 2009, The Journal of Immunology.
[6] S. Sano,et al. Prevention of toxic epidermal necrolysis by regulatory T cells , 2005, European journal of immunology.